How therapy mix, precision medicines, and portfolio diversification are reshaping oncology trend forecasting
Medicare Part D oncology spending is being shaped by a widening gap between prescription volume and allowed cost.
Wakely’s latest analysis of Medicare Part D oral oncology spending found that a small group of higher-cost, targeted therapies account for most oncology allowed costs, while older and lower-cost therapies continue to drive prescription utilization. As a result, recent Part D oncology trend is increasingly influenced by therapy mix, treatment duration, expanded indications, and the continued introduction of precision medicines—not prescription volume alone.
DOWNLOAD NOWRethinking Oncology Trend, Part II: Portfolio Diversification in Medicare Part D Oncology examines Medicare Part D oncology spending and utilization from 2019 through 2025 using prescription drug event data from approximately 11 million member months across 60 Medicare plans.
Key findings include:
- The 10 highest-cost oncology drugs account for approximately 60% of total oncology allowed cost.
- The 10 most frequently utilized drugs account for approximately 90% of oncology prescription utilization but less than 5% of total oncology allowed cost.
- The higher-cost therapies driving spending are largely different from the mature therapies driving prescription volume.
- Patients receiving high-cost and high-utilization therapies represent largely distinct populations.
- Part D oncology spending increasingly reflects portfolio diversification rather than the adoption or replacement of a single dominant therapy.
The analysis introduces the Portfolio Diversification Model, a framework for understanding how multiple targeted therapies collectively produce sustained spending growth while legacy therapies continue to anchor utilization.
For Medicare Advantage organizations, these findings point to the need for mix-driven forecasting models that account for:
- Changes in therapy mix
- New precision-medicine entrants
- Expanded treatment indications
- Treatment duration
- Generic and biosimilar competition
- The potential impact of Medicare drug price negotiation
This white paper complements Wakely’s Part I analysis of Medicare Part B oncology spending (What Medicare Data Reveals About Oncology Spending Trends, Innovation, and Cost Forecasting), which examined how therapeutic adoption and replacement influence oncology trend.
Download the white paper to explore the data, findings, and implications for Medicare oncology forecasting.
